The University of Michigan (U-M) Comprehensive Cancer Center has launched an Internet site to serve the growing online community of cancer patients seeking trustworthy medical information. The web site, which is located at
The University of Michigan (U-M) Comprehensive Cancer Center has launched an Internet site to serve the growing online community of cancer patients seeking trustworthy medical information. The web site, which is located at www.cancer.med.umich.edu, features information on University of Michigan cancer research and patient care services that previously was difficult to access from home.
We can now offer the public access to our clinical trials database, which includes easy-to-understand descriptions of more than 100 investigational treatments for nearly every type
and stage of cancer, says Max S.Wicha, MD, breast oncologist and director of the cancer center. Physicians in the community will find this database a valuable resource for referring their patients to cancer center clinical trials.
In another section, current and prospective patients can learn about the cancer centers history and current happenings. The Learn About Cancer section contains information about specific cancers, treatments and side effects, nutrition, clinical trials, and support groups. In addition, the site provides links to hundreds of cancer-related web sites that have been screened and approved by University of Michigan physicians
Our web site also allows anyone to send an e-mail message to U-Ms Cancer AnswerLine nurses, who give personalized answers to cancer care questions and refer patients to appropriate U-M physicians, Dr. Wicha says.
Cancer center patients will find the sites Guide for Patients useful. It helps them understand what they can expect during their visit, gives them phone numbers they might need, and provides maps to the University of Michigan Health System. All of the cancer centers publications can be found online as well. Another section of the site, Share the Hope and Humor, which is spearheaded by a cancer survivor, offers inspirational stories, thoughts and imagesand invites visitors to contribute their personal insights.
For health professionals, the site offers a section devoted to updates on research projects, continuing medical education opportunities, and a referral guide.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.